1.
J Med Chem
; 50(5): 897-900, 2007 Mar 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17269759
RESUMO
Optimization of a pyrrolidine-based template using structure-based design and physicochemical considerations has provided a development candidate 20b (3082) with submicromolar potency in the HCV replicon and good pharmacokinetic properties.
Assuntos
Antivirais/síntese química , Hepacivirus/efeitos dos fármacos , Pirrolidinas/síntese química , RNA Polimerase Dependente de RNA/antagonistas & inibidores , Animais , Antivirais/química , Antivirais/farmacologia , Sítios de Ligação , Disponibilidade Biológica , Chlorocebus aethiops , Hepacivirus/enzimologia , Modelos Moleculares , Pirrolidinas/química , Pirrolidinas/farmacologia , RNA Polimerase Dependente de RNA/química , Ratos , Estereoisomerismo , Relação Estrutura-Atividade , Células Vero
2.
Bioorg Med Chem Lett
; 16(14): 3784-8, 2006 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16697194
RESUMO
A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating an alanylamide P4 group, was designed and synthesised. Within this series, the N-2-(morpholin-4-yl)-2-oxoethyl derivative 24 was shown to be a potent, selective fXa inhibitor with good anticoagulant activity. Moreover, 24 possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species.